{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T21:28:13Z","timestamp":1668029293383},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Abbvie Ecuador"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12913-016-1671-4","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T12:49:33Z","timestamp":1472215773000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital"],"prefix":"10.1186","volume":"16","author":[{"given":"Luis","family":"Manjarres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda C.","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fornasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelin","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"1671_CR1","first-page":"151","volume":"5","author":"L Braun","year":"2012","unstructured":"Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151\u201363.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"8","key":"1671_CR2","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/ndt\/gft388","volume":"29","author":"B Stengel","year":"2014","unstructured":"Stengel B, Combe C, Jacquelinet C, Briancon S, Fouque D, Laville M, Frimat L, Pascal C, Herpe YE, Deleuze JF, et al. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol Dial Transplant. 2014;29(8):1500\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"9888","key":"1671_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260\u201372.","journal-title":"Lancet"},{"issue":"2","key":"1671_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2215\/CJN.03420807","volume":"3","author":"AM Cusumano","year":"2008","unstructured":"Cusumano AM, Gonzalez Bedat MC. Chronic kidney disease in Latin America: time to improve screening and detection. Clin J Am Soc Nephrol. 2008;3(2):594\u2013600.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1671_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2369-14-114","volume":"14","author":"AK Singh","year":"2013","unstructured":"Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS PG, et al. Epidemiology and risk factors of chronic kidney disease in India\u2013results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013;14:114.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1671_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","volume":"35","author":"R Thomas","year":"2008","unstructured":"Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329\u201344. vii.","journal-title":"Prim Care"},{"issue":"Suppl 5","key":"1671_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_5.28","volume":"17","author":"TB Drueke","year":"2002","unstructured":"Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant. 2002;17 Suppl 5:28\u201331.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1671_CR8","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208\u201318.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1671_CR9","first-page":"397","volume":"13","author":"MS Joy","year":"2007","unstructured":"Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5):397\u2013411.","journal-title":"J Manag Care Pharm"},{"key":"1671_CR10","volume-title":"PREVALENCIA DE HIPERPARATIROIDISMO SECUNDARIO EN PACIENTES SOMETIDOS A HEMODI\u00c1LISIS\u201d CENTRO DE DIALISIS \u201cDR. CARLOS ELIZALDE MONTEVERDE\u201d","author":"J Ramirez","year":"2010","unstructured":"Ramirez J. PREVALENCIA DE HIPERPARATIROIDISMO SECUNDARIO EN PACIENTES SOMETIDOS A HEMODI\u00c1LISIS\u201d CENTRO DE DIALISIS \u201cDR. CARLOS ELIZALDE MONTEVERDE\u201d. Guayaquil: UNIVERSIDAD DE GUAYAQUIL; 2010."},{"key":"1671_CR11","volume-title":"EFECTOS COLATERALES POR LA DISMINUCI\u00d3N DEL CALCIO EN PACIENTES CON INSUFICIENCIA RENAL CR\u00d3NICA ATENDIDOS EN LA UNIDAD RENAL CONTIGO DE LA CIUDAD DE LATACUNGA EN EL PERIODO OCTUBRE 2011\u2013FEBRERO 2012","author":"M Tapia","year":"2012","unstructured":"Tapia M. EFECTOS COLATERALES POR LA DISMINUCI\u00d3N DEL CALCIO EN PACIENTES CON INSUFICIENCIA RENAL CR\u00d3NICA ATENDIDOS EN LA UNIDAD RENAL CONTIGO DE LA CIUDAD DE LATACUNGA EN EL PERIODO OCTUBRE 2011\u2013FEBRERO 2012. Ambato: Universidad T\u00e9cnica de Ambato; 2012."},{"issue":"1","key":"1671_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1523-1755.2004.00733.x","volume":"66","author":"WL St Peter","year":"2004","unstructured":"St Peter WL, Khan SS, Ebben JP, Pereira BJ, Collins AJ. Chronic kidney disease: the distribution of health care dollars. Kidney Int. 2004;66(1):313\u201321.","journal-title":"Kidney Int"},{"issue":"3","key":"1671_CR13","doi-asserted-by":"crossref","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","volume":"27","author":"M Kerr","year":"2012","unstructured":"Kerr M, Bray B, Medcalf J, O\u2019Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(3):iii73\u201380.","journal-title":"Nephrol Dial Transplant"},{"key":"1671_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2458-8-117","volume":"8","author":"QL Zhang","year":"2008","unstructured":"Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.","journal-title":"BMC Public Health"},{"key":"1671_CR15","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1111\/j.1523-1755.2005.09806.x","volume":"98","author":"B Rodriguez-Iturbe","year":"2005","unstructured":"Rodriguez-Iturbe B, Bellorin-Font E. End-stage renal disease prevention strategies in Latin America. Kidney Int Suppl. 2005;98:S30\u201336.","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"1671_CR16","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1681\/ASN.2007020220","volume":"18","author":"RN Foley","year":"2007","unstructured":"Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007;18(10):2644\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"1671_CR17","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1177\/089686080902902S45","volume":"29","author":"R Pecoits-Filho","year":"2009","unstructured":"Pecoits-Filho R, Campos C, Cerdas-Calderon M, Fortes P, Jarpa C, Just P, Luconi P, Lugon JR, Pacheco A, Paniagua R, et al. Policies and health care financing issues for dialysis in Latin America: extracts from the roundtable discussion on the economics of dialysis and chronic kidney disease. Perit Dial Int. 2009;29 Suppl 2:S222\u2013226.","journal-title":"Perit Dial Int"},{"issue":"3","key":"1671_CR18","first-page":"210","volume":"6","author":"P Bolasco","year":"2009","unstructured":"Bolasco P. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review. Clin Cases Miner Bone Metab. 2009;6(3):210\u20139.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"1671_CR19","volume-title":"SISPRO Aplicativos Misionales","author":"Ministerio de Salud y Protecci\u00f3n Social","year":"2016","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. In: Social SIdIdlP, editor. SISPRO Aplicativos Misionales. Colombia: Ministerio de Salud y Protecci\u00f3n Social; 2016."},{"key":"1671_CR20","volume-title":"Sistema Oficial de Contrataci\u00f3n P\u00fablica","author":"Ecuador GNdlRd","year":"2016","unstructured":"Ecuador GNdlRd. Sistema Oficial de Contrataci\u00f3n P\u00fablica. Ecuador: Ecuador GNdlRd; 2016."},{"issue":"6","key":"1671_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","volume":"26","author":"M Naves-Diaz","year":"2011","unstructured":"Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin JL, Rodriguez-Puyol D, Cannata-Andia JB. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011;26(6):1938\u201347.","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Suppl 5","key":"1671_CR22","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(5 Suppl 5):S45\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"4 Suppl 3","key":"1671_CR23","first-page":"S1","volume":"42","author":"F National Kidney","year":"2003","unstructured":"National Kidney F. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1\u2013201.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1671_CR24","first-page":"59","volume":"22","author":"A Capuano","year":"2009","unstructured":"Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009;22(1):59\u201368.","journal-title":"J Nephrol"},{"issue":"5","key":"1671_CR25","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","volume":"19","author":"DG Dobrez","year":"2004","unstructured":"Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1671_CR26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1185\/03007990902844097","volume":"25","author":"M Nuijten","year":"2009","unstructured":"Nuijten M, Andress DL, Marx SE, Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin. 2009;25(5):1221\u201334.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1671_CR27","doi-asserted-by":"publisher","first-page":"A467","DOI":"10.1016\/j.jval.2014.08.1313","volume":"17","author":"V Lorenzoni","year":"2014","unstructured":"Lorenzoni V, Pierotti F, Turchetti G. A Budget Impact Analysis (Bia) Of The Use Of Paricalcitol For The Treatment Of Secondary Hyperparathyroidism (Shpt) In End Stage Renal Disease Patients. Value Health. 2014;17(7):A467.","journal-title":"Value Health"},{"issue":"7","key":"1671_CR28","doi-asserted-by":"publisher","first-page":"A688","DOI":"10.1016\/j.jval.2013.08.2048","volume":"16","author":"JL Sanchez-Casillas","year":"2013","unstructured":"Sanchez-Casillas JL, Ramirez-Lopez-De-N MG. Long-Term Cost Comparison Between Paricalcitol and Calcitriol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in Mexico. Value Health. 2013;16(7):A688.","journal-title":"Value Health"},{"issue":"4","key":"1671_CR29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483\u201390.","journal-title":"Kidney Int"},{"issue":"3","key":"1671_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/tcrm.2006.2.3.297","volume":"2","author":"S Cheng","year":"2006","unstructured":"Cheng S, Coyne D. Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease. Ther Clin Risk Manag. 2006;2(3):297\u2013301.","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"1671_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2165\/00044011-200626110-00002","volume":"26","author":"H Rosery","year":"2006","unstructured":"Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig. 2006;26(11):629\u201338.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1671_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118174","volume":"10","author":"E Riccio","year":"2015","unstructured":"Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M, Pisani A. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS One. 2015;10(3), e0118174.","journal-title":"PLoS One"},{"issue":"11","key":"1671_CR33","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jcph.556","volume":"55","author":"B Afsar","year":"2015","unstructured":"Afsar B, Agca E, Turk S. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin Pharmacol. 2015;55(11):1280\u20135.","journal-title":"J Clin Pharmacol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-016-1671-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-016-1671-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-016-1671-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:17:41Z","timestamp":1601047061000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-016-1671-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1671"],"URL":"https:\/\/doi.org\/10.1186\/s12913-016-1671-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]},"article-number":"443"}}